Losartan Market Research Reveals Path To $1.83 Billion By 2030

The losartan market is positioned for consistent expansion over the coming years, driven by several healthcare trends and demographic factors. With increasing awareness of cardiovascular health and advances in drug formulations, this sector is expected to evolve significantly by 2030. Let's explore the market valuation, key players, prominent trends, and segment breakdowns shaping the future of the losartan industry.

Projected Market Value and Growth of the Losartan Market
The valuation of the losartan market is forecasted to reach $1.83 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.3%. This upward trend is fueled by the aging population, which naturally increases the incidence of hypertension and related kidney issues. In addition, the rising demand for antihypertensive drugs with kidney-protective properties and broader availability of affordable generic versions contribute significantly to this growth. Healthcare providers are placing greater emphasis on stroke prevention and chronic disease management, which also supports the expansion of the losartan market.

The losartan market size has grown steadily in recent years. It will grow from $1.49 billion in 2025 to $1.55 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing global hypertension burden, widespread clinical adoption of arbs, rising incidence of diabetes-related kidney disease, improved awareness of cardiovascular risk management, early shift from ace inhibitors to arbs.

Download a free sample of the losartan market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24284&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

The market is further propelled by the growing prevalence of hypertension and cardiovascular disorders worldwide. Patients and clinicians are increasingly favoring angiotensin receptor blockers (ARBs) like losartan over ACE inhibitors due to their efficacy and patient tolerance. Additionally, generic losartan prescriptions are becoming more widespread, and the medication is gaining traction in managing diabetic nephropathy. Long-term adoption of blood pressure control therapies is also rising, solidifying a strong demand base for losartan products.

Key Players Driving the Losartan Market Forward
Several pharmaceutical companies hold significant market shares in the losartan landscape. Leading manufacturers include Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, and JPM Pharma & Chemicals Pvt. Ltd.

View the full losartan market report:
https://www.thebusinessresearchcompany.com/report/losartan-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

A notable collaboration occurred in April 2025, when US-based Scienture Holdings, Inc. partnered with Saptalis Pharmaceuticals to produce Arbli, a losartan potassium oral suspension with a concentration of 10 mg/mL. This alliance also involves warehousing and distribution agreements to ensure smooth market availability of Arbli, which is the first FDA-approved ready-to-use oral liquid losartan. This innovative formulation is designed to address unmet patient needs in hypertension treatment, offering an alternative for those who have difficulty swallowing tablets.

Emerging Trends Transforming the Losartan Industry
The losartan market is witnessing a push towards innovation, particularly in new drug formulations that improve patient compliance. One key example is the development and regulatory approval of losartan potassium oral suspensions. These liquid forms ease administration for populations such as children and elderly patients who may struggle with traditional tablets.

For instance, in March 2025, Scienture Holdings Inc. received FDA approval for Arbli, a convenient, ready-to-use liquid formulation intended to treat hypertension, reduce stroke risk in hypertensive patients with left ventricular hypertrophy, and manage diabetic nephropathy in type 2 diabetes. Arbli offers precise dosing without the need for compounding and comes in a 165 mL peppermint-flavored suspension (10 mg/mL) with an 18-month shelf life at room temperature, enhancing ease of use and patient adherence.

Detailed Breakdown of Losartan Market Segments
This report organizes the losartan market into several important segments for a comprehensive understanding:

1) Dosage Form: Tablets, Powder, Suspension
2) Source of Production: Contract Manufacturing Organizations (CMOs), In-House Manufacturing
3) Distribution Channels: Online Platforms, Offline Retail
4) Therapeutic Applications: Hypertension, Stroke, Diabetic Nephropathy, Other Conditions
5) End-User Groups: Adults, Pediatric Patients

Further subcategories within dosage forms include tablet strengths of 25 mg, 50 mg, and 100 mg; powder variants in the same doses; and suspension forms available in 5 mg/5 mL, 10 mg/5 mL, and 25 mg/5 mL concentrations. These precise classifications help stakeholders understand market dynamics and consumer preferences across various treatment needs and delivery methods.

Our 2026 market reports now offer broader strategic coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.